Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy: A Propensity Score Analysis and Predictors of Care for Patients With Brain Metastases From Breast Cancer.

abstract：BACKGROUND:Ovarian suppression from chemotherapy results in bone loss in premenopausal women with breast cancer (BC). Less is known about bone microarchitecture changes. We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to measure volumetric bone density and trabecular and cortical microarch...

journal_title：Clinical breast cancer

authors： Hopson MB,Onishi M,Awad D,Buono D,Maurer M,Crew KD,Shane E,Hershman DL,Kalinsky K

更新日期：2020-06-01 00:00:00

abstract：INTRODUCTION:Dose-dense therapies have had a major effect on reducing toxicity and improving outcomes in breast cancer. A combination of TC every 3 weeks has emerged as a common chemotherapy regimen used for treatment of node-negative or lower-risk node-positive breast cancer. We tested whether it is feasible to delive...

journal_title：Clinical breast cancer

authors： Burkard ME,Wisinski KB,Njiaju UO,Donohue S,Hegeman R,Stella A,Mansky P,Shah V,Goggins T,Qamar R,Dietrich L,Kim K,Traynor AM,Tevaarwerk AJ

更新日期：2014-06-01 00:00:00

abstract：BACKGROUND:There is no sufficient evidence to establish a standard of care for patients with brain metastases (BM) from HER2+ breast cancer (BC). The aim of this study was to assess the impact of local and systemic treatments on the outcome of patients diagnosed with BM from HER2+ BC over a period of 10 years, from 200...

journal_title：Clinical breast cancer

authors： Gori S,Puglisi F,Moroso S,Fabi A,La Verde N,Frassoldati A,Tarenzi E,Garrone O,Vici P,Laudadio L,Cretella E,Turazza M,Foglietta J,Leonardi V,Cavanna L,Barni S,Galanti D,Russo A,Marchetti F,Valerio M,Lunardi G,Alo

更新日期：2019-08-01 00:00:00

abstract：BACKGROUND:The [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program is defined as cancer screening for asymptomatic subjects using FDG-PET/computed tomography with or without combination of other screening tests. The aim of this study was to analyze the detection rate and effectivene...

journal_title：Clinical breast cancer

authors： Minamimoto R,Senda M,Jinnouchi S,Terauchi T,Yoshida T,Inoue T

更新日期：2015-04-01 00:00:00

abstract：:According to the World Health Organization (WHO) published data in 2015; breast cancer is the most prevalent and the second leading cause of cancer death among females. As approximately 70% of breast cancer tumor cells are estrogen receptor (ER) positive, primary therapeutic agents such as Anti-estrogens were produced...

journal_title：Clinical breast cancer

authors： Teymourzadeh A,Mansouri S,Farahmand L,Hosseinzade A,Majidzadeh-A K

更新日期：2017-10-01 00:00:00

abstract：:This article attempts to provide the reader with a complete overview of topoisomerase (topo) II alpha as a marker for predicting the efficacy of anthracyclines in patients with breast cancer. In the first section of this article, in vitro data supporting the predictive value of topo II alpha are reviewed. Interestingl...

journal_title：Clinical breast cancer

authors： Di Leo A,Isola J

更新日期：2003-08-01 00:00:00

abstract：:The development of third-generation aromatase inhibitors (AIs) has brought about a major change in the therapeutic approach to patients with hormone-sensitive breast cancer. In randomized clinical trials, each of the third-generation AIs has demonstrated efficacy in the adjuvant treatment of postmenopausal women with ...

journal_title：Clinical breast cancer

authors： Henderson IC,Piccart-Gebhart MJ

更新日期：2005-08-01 00:00:00

abstract：BACKGROUND:Several studies conducted in developed countries introduced diet and physical inactivity as major risk factors for several types of cancers. However, the impact of diet and physical inactivity on the risk of breast cancer (BC) is understudied, and the limited findings are controversial. In addition, no or li...

journal_title：Clinical breast cancer

authors： Fararouei M,Iqbal A,Rezaian S,Gheibi Z,Dianatinasab A,Shakarami S,Dianatinasab M

更新日期：2019-02-01 00:00:00

abstract：:Adherence to endocrine therapy (ET) is a longstanding problem in breast cancer (BC) survivorship care, particularly among younger women. Younger patients have reported lower ET initiation rates and greater rates of early discontinuation and are considered an "at risk" group for nonadherence. For women who hope to have...

journal_title：Clinical breast cancer

authors： Benedict C,Thom B,Teplinsky E,Carleton J,Kelvin JF

更新日期：2017-06-01 00:00:00

abstract：BACKGROUND:Aromatase inhibitor therapy is often effective for breast cancer, yet it can be accompanied by musculoskeletal pain and stiffness. This prevalence assessment aimed to characterize a rheumatologist's view of frequency and clinical features, including associated disability, within a breast cancer clinic panel ...

journal_title：Clinical breast cancer

authors： Moxley G

更新日期：2010-04-01 00:00:00

abstract：BACKGROUND:Activation of the JAK/STAT pathway is common in triple-negative breast cancer (TNBC) and affects the expression of genes controlling immune signaling. A subset of TNBC cases will have somatic amplification of chromosome 9p24.1, encoding PD-L1, PD-L2, and JAK2, which has been associated with decreased surviva...

journal_title：Clinical breast cancer

authors： Chen M,Pockaj B,Andreozzi M,Barrett MT,Krishna S,Eaton S,Niu R,Anderson KS

更新日期：2018-10-01 00:00:00

abstract：BACKGROUND:Recent observational studies are concerning because they document rising mastectomy rates coinciding with more than a dozen reports that lumpectomy has better overall survival (OS) than mastectomy. Our aim was to determine if there were differences in OS of matched breast cancer patients undergoing lumpectom...

journal_title：Clinical breast cancer

authors： Landercasper J,Ramirez LD,Borgert AJ,Ahmad HF,Parsons BM,Dietrich LL,Linebarger JH

更新日期：2019-06-01 00:00:00

abstract：INTRODUCTION:Unwanted clinical variation is common across the United States health care system and is particularly vexing in oncology owing to the complexity, morbidity, and high cost of the disease. Efforts to standardize care including guidelines and continuing medical education have had only limited impact. Disease-...

journal_title：Clinical breast cancer

authors： Colonna S,Sweetenham J,Burgon TB,Buys SS,Lynch R,Au T,Johnson E,Kubal T,Paculdo D,Acelajado MC,Peabody JW

更新日期：2019-04-01 00:00:00

abstract：:Over the past 30 years, much progress has been made in adjuvant chemotherapy for patients with early-stage breast cancer. The introduction of anthracyclines and, recently, taxanes has significantly improved the efficacy of adjuvant chemotherapy and has provided useful insight regarding future development of even more ...

journal_title：Clinical breast cancer

authors： Mamounas EP,Geyer CE Jr,Swain SM

更新日期：2004-01-01 00:00:00

abstract：PURPOSE:The 8th edition of the American Joint Committee on Cancer (AJCC) breast cancer staging system requires histologic grade (GR), estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and stage (assessed by the tumor, node, metastasis classification system). For T1-2 N...

journal_title：Clinical breast cancer

authors： Breaux A,Turner B,Wu X,Rai SN,Riley EC,Mandadi M,Sanders MA

更新日期：2019-02-01 00:00:00

abstract：INTRODUCTION:Until now, no studies have investigated whether women other than those with dense breasts are suitable for adjunctive ultrasonography after negative mammography, and investigated whether all women with negative mammography are suitable for adjunctive ultrasonography. METHODS:Based on the Multi-modality In...

journal_title：Clinical breast cancer

authors： Dong H,Huang Y,Song F,Dai H,Liu P,Zhu Y,Wang P,Han J,Hao X,Chen K

更新日期：2018-06-01 00:00:00

abstract：BACKGROUND:Arm lymphedema is a common complication after axillary lymph node dissection (ALND), and there is no effective treatment. The clinical significance of sentinel lymph node biopsy (SLNB) is to avoid the risk of arm lymphedema caused by ALND in cases in which the nodes are negative for cancer cells. In develope...

journal_title：Clinical breast cancer

authors： Li J,Jia S,Zhang W,Zhang Y,Qiu F,Xue J,Gu X

更新日期：2013-06-01 00:00:00

abstract：:Mucin-1 (MUC-1) is a high-molecular-weight glycoprotein rich in serine and threonine residues that are O-glycosylated. Expression of MUC-1 is increased in breast, ovarian, and other adenocarcinomas, and altered glycosylation results in exposure of novel peptide epitopes and the expression of tumor-associated carbohydr...

journal_title：Clinical breast cancer

authors： Miles D,Papazisis K

更新日期：2003-02-01 00:00:00

abstract：:Bisphosphonates (BPs) are approved for preventing the skeletal-related events associated with malignant bone disease. Several studies indicate that they may also prevent cancer therapy-induced bone loss. Multiple preclinical and early clinical studies provide evidence of the anticancer activity of BPs, including an in...

journal_title：Clinical breast cancer

authors： Mahtani R,Jahanzeb M

更新日期：2010-10-01 00:00:00

abstract：BACKGROUND:Eribulin has efficacy in patients with progression after ≥ 1 chemotherapeutic regimen for metastatic breast cancer (MBC). A short disease-free interval (DFI) and previous use of taxanes in the neoadjuvant or adjuvant setting have been associated with worse outcomes for patients receiving first-line chemother...

journal_title：Clinical breast cancer

authors： Ortega V,Antón A,Garau I,Afonso N,Calvo L,Fernández Y,Martínez-García M,Blanco E,Zamora P,García M,Illarramendi JJ,Rodríguez Sánchez CA,Sampayo M,Aguirre E,Pérez-García JM,Cortés J,Llombart-Cussac A

更新日期：2019-04-01 00:00:00

abstract：PURPOSE:In order to evaluate the feasibility of dose-dense docetaxel followed by dose-dense AC (doxorubicin/cyclophosphamide) as adjuvant chemotherapy for operable breast cancer, we conducted a phase II study. PATIENTS AND METHODS:In cohort 1, 28 patients received docetaxel 100 mg/m2 followed by doxorubicin 60 mg/m2 w...

journal_title：Clinical breast cancer

authors： Lambert-Falls R,Modugno S

更新日期：2007-08-01 00:00:00

abstract：BACKGROUND:Spontaneous rib fractures (SRFs) are defined as fractures without apparent blunt force trauma. This study evaluated the incidence and risk factors of SRFs after treatment of patients with breast cancer based on bone scans. In addition, we analyzed radiation-associated SRFs and identified radiotherapy (RT) fa...

journal_title：Clinical breast cancer

authors： Kim DW,Kim JS,Kim K,Shin KH

更新日期：2020-07-23 00:00:00

abstract：:Breast-conserving therapy (BCT) consists of segmental mastectomy followed by postoperative radiation therapy (RT) to the whole breast. At least 6 prospective randomized trials have proven the equivalence of BCT to mastectomy. However, BCT remains underused and, most importantly, a sizable proportion of patients with i...

journal_title：Clinical breast cancer

authors： Truong MT,Hirsch AE,Formenti SC

更新日期：2003-10-01 00:00:00

abstract：BACKGROUND:The prognostic/predictive value of aberrant MYC gene copies and protein expression is not clear in breast cancer. PATIENTS AND METHODS:Early breast cancer patients were treated with anthracycline-containing chemotherapy within 2 randomized adjuvant trials. MYC gene and centromere-8 status, as well as Myc pr...

journal_title：Clinical breast cancer

authors： Batistatou A,Kotoula V,Bobos M,Kouvatseas G,Zagouri F,Tsolaki E,Gogas H,Koutras A,Pentheroudakis G,Timotheadou E,Pervana S,Goussia A,Petraki K,Sotiropoulou M,Koletsa T,Razis E,Kosmidis P,Aravantinos G,Papadimitriou C

更新日期：2018-02-01 00:00:00

abstract：:The androgen receptor (AR) is increasingly considered as a potential biomarker for breast cancer. Nevertheless, the prognostic value of AR expression in patients with triple negative breast cancer (TNBC) remains controversial. Therefore, in this meta-analysis, we investigated AR expression and its impact on survival o...

journal_title：Clinical breast cancer

authors： Xu M,Yuan Y,Yan P,Jiang J,Ma P,Niu X,Ma S,Cai H,Yang K

更新日期：2020-08-01 00:00:00

abstract：:Over the past 30 years there has been an increased use of neoadjuvant (or primary) chemotherapy for treating patients with breast cancer. However, while it is clear that chemotherapy given in the adjuvant setting after surgery does prolong patients' overall and disease-free survival, the evidence that chemotherapy in ...

journal_title：Clinical breast cancer

authors： Heys SD,Hutcheon AW,Sarkar TK,Ogston KN,Miller ID,Payne S,Smith I,Walker LG,Eremin O,Aberdeen Breast Group.

更新日期：2002-10-01 00:00:00

abstract：INTRODUCTION:Implant-sparing mastectomy (ISM) is a skin-sparing mastectomy that preserves a retropectoral implant and potentially eliminates the need for tissue expansion or complex reconstruction. This study aimed to determine oncologic and surgical outcomes and reconstructive patterns in patients undergoing ISM. PAT...

journal_title：Clinical breast cancer

authors： Burke EE,Laronga C,Sun W,DeBiase S,Naqvi SMH,Fridley B,Czerniecki BJ,Hoover SJ,Khakpour N,Kiluk JV,Lee MC

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:Elderly patients form a large proportion of patients with breast cancer but are underrepresented in clinical trials. We examined whether elderly patients experience more toxicity than younger patients within breast cancer clinical trials. MATERIALS AND METHODS:All breast cancer trials open from 1999 to 2012...

journal_title：Clinical breast cancer

authors： Mariano C,Francl M,Pope J,Wong L,Lim HJ,Lohrisch C

更新日期：2015-02-01 00:00:00

abstract：UNLABELLED:This is a retrospective study on 40 breast cancer patients, of which 20 have bone metastases, 10 have visceral metastases, and 10 have no evidence of disease, aimed at evaluating the role of CXCR4 and the RANK/RANKL/OPG system to predict bone metastases. CXCR4 expression, alone or in combination with RANK, i...

journal_title：Clinical breast cancer

authors： Ibrahim T,Sacanna E,Gaudio M,Mercatali L,Scarpi E,Zoli W,Serra P,Ricci R,Serra L,Kang Y,Amadori D

更新日期：2011-12-01 00:00:00

abstract：BACKGROUND:We aimed to evaluate the incidence of acute toxicity in a 3-week accelerated radiation therapy (RT) schedule with a concomitant boost compared with the 6.5-week conventional schedule with a sequential boost for early-stage, node-negative breast cancer. MATERIALS AND METHODS:This study included the first 50 ...

journal_title：Clinical breast cancer

authors： Chadha M,Vongtama D,Friedmann P,Parris C,Boolbol SK,Woode R,Harrison LB

更新日期：2012-02-01 00:00:00